{"id":"hpv9v","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Injection site pain"},{"rate":"25-35","effect":"Injection site swelling"},{"rate":"20-30","effect":"Injection site erythema"},{"rate":"10-15","effect":"Fever"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains virus-like particles (VLPs) derived from nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58) that trigger both humoral and cellular immune responses. This immunization prevents infection by these HPV strains, thereby reducing the risk of cervical cancer, other anogenital cancers, and oropharyngeal cancers in vaccinated individuals.","oneSentence":"HPV9v is a 9-valent human papillomavirus vaccine that stimulates immune responses against nine HPV types to prevent infection and HPV-related cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:04.448Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer and precancerous lesions caused by HPV types 16, 18, 31, 33, 45, 52, and 58"},{"name":"Prevention of genital warts caused by HPV types 6 and 11"},{"name":"Prevention of other HPV-related anogenital and oropharyngeal cancers"}]},"trialDetails":[{"nctId":"NCT03626467","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2018-10-15","conditions":"HIV Infections","enrollment":158}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gardasil9"],"phase":"marketed","status":"active","brandName":"HPV9v","genericName":"HPV9v","companyName":"Fundacion SEIMC-GESIDA","companyId":"fundacion-seimc-gesida","modality":"Biologic","firstApprovalDate":"","aiSummary":"HPV9v is a nonavalent vaccine against human papillomavirus. It is being studied in a clinical trial (NCT03626467) to evaluate its immunogenicity in men infected with HIV who have sex with men.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}